CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Tranexamic acid may lighten dark skin patches due to melasma and other skin conditions. Learn about the benefits, risks, and ...

According to a new comprehensive report from The Insight Partners, the colonoscopy devices market is witnessing significant ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You accept for the main domain ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody prasinezumab even though it missed the bar in a mid-stage trial late last year.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the polyneuropathy manifestations of ATTR amyloidosis and hereditary transthyretin ...

Elsie soon learned the cause - cardiac amyloidosis. "We used to think of it more as a rare disease," says Dr. Carly Fabrizio of Temple Health. But Dr. Fabrizio says heart failure specialists like ...

Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.